Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

It’s been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...

Hims & Hers Health (NYSE:HIMS) is rewriting the telehealth playbook while its competitors scramble. With a 200% YTD surge, the company's diversified approachcombining virtual consultations ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...

Hers provides medications for weight loss, hair loss, mental health, sexual health, and more. Here’s the lowdown on how it works and what it costs. Share on Pinterest Hers, a part of the Hims ...